Welcome to Merz Therapeutics North America

At Merz Therapeutics, we seek to address the unique needs of people who suffer from movement disorders, neurological conditions, and other health conditions that severely impact patients’ quality of life.

Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is headquartered in Frankfurt, Germany and is represented in more than 90 countries. Our Merz Therapeutics North America business is composed of affiliates in the U.S. and Canada and has regional headquarters in Raleigh, N.C. To visit the Merz Canada website and for more information on our Canada business, please click here.

Merz Pharmaceuticals GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that serve unmet patient and customer needs.

News

MERZ THERAPEUTICS DONATES $100,000 TO SUPPORT CONSTRUCTION OF NEW REHABILITATION CENTER AT UNIVERSITY OF NORTH CAROLINA

Merz Therapeutics announced today its U.S. organization has made a $100,000 donation to the University of North Carolina (UNC) Health Foundation to assist in funding construction and capital expenses of UNC Health’s new Acute Inpatient Rehabilitation Center (the “AIR Center”), scheduled to open in Hillsborough, N.C. in February 2022.

Read More

XEOMIN® (INCOBOTULINUMTOXINA) SAFETY AND EFFICACY DATA FOR TREATMENT OF PEDIATRIC CHRONIC SIALORRHEA PUBLISHED IN NEUROLOGY

Merz Therapeutics announced today the online publication of the article “SIPEXI: Placebo-controlled clinical trial of incobotulinumtoxinA for sialorrhea in children” in Neurology, the premier peer-reviewed journal for clinical neurology research.

Read More

MERZ THERAPEUTICS TO PRESENT KEY DATA ON XEOMIN® (incobotulinumtoxinA) AT TOXINS 2021 VIRTUAL CONFERENCE

Merz Therapeutics announced today the presentation of data from 18 accepted abstracts on XEOMIN® (incobotulinumtoxinA) at TOXINS 2021: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins, taking place virtually January 16 and 17.

Read More